The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Isnât it interesting that the Abingdon RNS is the same but also has more info on the results of the trial (which were very good) yet ODX omits this data - no reason I can think of to omit it when it is so positive - annoying
why is Colin providing info about the company in this way - they pay Wallbrook for PR, do it that way. I would prefer formal updates - I donât hold a six figure holding to be given company info by some mate of Colinâs down the pub.
Really is not a professional look.
why would it be delayed?
For a wild guess, it didnât start until later in December than we think and remember, Mologic only CEâed the test right before Xmas.
TT will come soon - I suspect the confirmation its complete, govt approval and orders will all run pretty close to each other
I personally donât think it can be the AVCT test we will be doing for the following:
- AVCT test canât be CE marked (Mologic is)
- AVCT wxpects CE marking etc end of March
- that would then need to be TTâed which would add some time on to the manufacturing
Fact is that Omega tweeted about producing 2m per week in April suggests that will be Mologic - I also suspect by June there will be 3 soverign tests - Mologic, AVCT and Surescreen.
Aberdeenman - I 100% agree
They send out broad RNS's that it is obvious more detail is needed and like today, the impact on the SP. They had a whole weekend to figure this out (the impact to SP of the director sells) - would not have taken someone with a bit of foresight to provide an update on the reason - a quick tweet by Walbrook this morning saying all is good does not really cut it when down 8% already.
Really need to stabilise the SP movements to increase PI and II interest - just clarify, thats all - more details.
"I predicted last week the gap was starting to fill, support should be around 72p let's see if it is hit tomorrow."
Lets hope it does not hit 72p as that would be yet another naff day!
Ok, lets look at this another way.........
Does anyone think 4 directors would say 'oh shoot, we are about to do really badly and the SP crash - quick, lets all sell our options before the PI's can sell and hope the FCA does not notice this insider trading"
I have had a theory for a while that both the antigen and the antibody are for the same customer govt (DHSC) - not be surprised if it has been said to Omega to focus on antigen and go back to antibody at some later stage - 200k per week Abingdon can easily pick up.
Just a theory.....
early in the new year is pretty vague, but I think most people would class that by at least end of March?
"We have to wait for a TR1. I think they could have sold their remaining shares actually."
Does it matter if they are?
Fact is, the RNS yesterday did not clarify much - questions I keep seeing
- which test will we manufacture
- what will the profit be
- when will TT finish
- if govt is loaning us equipment, does that hurt our P&L and if so, how much by?
They then added that current financial year is a bit naff and sold hardly any Covid related items despite predicting a few months ago a decent year.
Then to cap this off, we get FINNCAP with a very conservative report on revenue and profits!
So the sell off is understandable IMHO until some details are known on the antigen side of things.
Additionally, silent on the TT - I like a lot of people expected it to be done by now. Likewise, the UKTRC test - 14th Feb is a key date - nothing on that either (appreciate it has to come from Abingdon but I am saying generally we have no news on this area)
Thus, I see the sell off people derisking - we could be in for a month or two of lack of clarity which I feel like we are in a perpetual state of with ODX sometimes!
Way I take it is the Mologic test is here and in progress.
ACVT RNS'ed the other day about a collaboration - I take it that they may combine the affirmer from AVCT with the Mologic test, though this is some way off.
In the meantime, we TT the Mologic test and then can change if needs be later on.
"It is the use of the past tense that is interesting it sounds as though they are now capable of 2m a week"
I don't get that, there is still snow outside yet some of the equipment still has wrapping on?
GDR has triple bagged in 30 days or so - if you look, they have had a mix of red and blue days......
Shocking I know, but shares don't only go in one direction - bit of consolidation around the 90's is fine until the next move up.
Relax and enjoy the ride - 1st of Feb we hit 60p
Kevin, this isnât exactly what they said at all.
Roche also do pharmaceuticals which have reduced during the covid crisis as routine medical has reduced - they expect that to increase in latter part of 2021.
https://www.roche.com/investors/updates/inv-update-2021-02-04.htm
I would assume PCR so they can track both if they have covid but also which 'version' - they seem pretty nervous about this South African mutation
âearly in the new yearâ which is fairly general but I would say early in the new year is up until end Feb?
FFS - have you seen the comments on the article about LFTâs - lots of people saying âthey donât workâ âpointlessâ âliverpool only found 2% of casesâ - Deeks and co have done a lot of damage to the LFT industry
This may be a pipe dream, but I suspect the following will happen:
- antibody testing will be needed long term - years, maybe forever
- covid antigen testing will be needed years, maybe forever
- mologic are working with Glasgow Uni to create an LFT that can tell you if you have covid / flu / cold - imagine how useful that would be - I suspect that will be the future of testing for LFT and a UK based group of companies producing it.....
Fingers crossed.....
Annoying contract - we donât know for months if we get an order from the government yet canât sell privately until government decide to confirm cancellation, all the while building up stock but unable to sell, possibly losing business
doh - sorry, my mistake - it would be equal to ours and Cigaâs
I was confusing myself with the split of production numbers - apologies.